Last reviewed · How we verify
Ergoferon
At a glance
| Generic name | Ergoferon |
|---|---|
| Sponsor | Materia Medica Holding |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2 (PHASE3)
- Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children (PHASE4)
- Study on Safety and Effectiveness of Ergoferon in the Treatment of Flu / ARVI in Outpatients.
- Clinical Trial of Safety and Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adults (PHASE3)
- Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children (PHASE4)
- Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza (PHASE4)
- Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children (PHASE3)
- Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ergoferon CI brief — competitive landscape report
- Ergoferon updates RSS · CI watch RSS
- Materia Medica Holding portfolio CI